Drug intelligence / Profile preview

acepifylline

Development stage
Unknown
Lead developer
Nabiqasim Industries
Modality
Small Molecules
Administration
Oral
01

Overview

Acefyl is a brand of bronchodilator medications developed and manufactured by Nabiqasim Industries, primarily containing **acepifylline** (acefylline piperazine). Acepifylline is a xanthine derivative related to theophylline that acts as a bronchodilator and respiratory stimulant. Its primary mechanism of action involves the non-selective inhibition of phosphodiesterase (PDE) enzymes, which leads to an increase in intracellular cyclic adenosine monophosphate (cAMP) levels, resulting in the relaxation of bronchial smooth muscle. Additionally, it acts as an adenosine receptor antagonist. Acefyl is indicated for the symptomatic treatment of respiratory disorders associated with bronchospasm, such as bronchial asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). The product line includes a single-agent formulation (Acefyl 125) and a multi-ingredient expectorant variant (Acefyl Cough) which contains additional components like diphenhydramine and ammonium chloride.

Brand names
AcefylAcefyl 125Acefyl125Acefyl-125Acefyl Cough
Other names
acefylline piperazine7-theophyllineacetic acid piperazine saltacefylline
02

Targets

ADORA2B (Adenosine A2B receptor)ADORA1 (Adenosine receptor A1 subtype)PDE4 (Phosphodiesterase 4A1)

Beyond the preview

Go deeper on acepifylline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on acepifylline.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call